Developer docs
API playgroundTry for free, no card

Search company profiles

AnaBios

Full company profile

uuid0002d3l

Namestring
AnaBios
Legal namestring
AnaBios Corporation
Websiteurl
anabios.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

AnaBios is a San Diego-based preclinical contract research organization founded in 2008 that provides human tissue-based translational research services to pharmaceutical, biotechnology, and academic clients. The company procures ethically consented adult human tissue and primary cells through an extensive network of US hospitals and organ procurement organizations, and applies proprietary preservation methods to deliver specimens with RNA Integrity Number scores 25-40% higher than competing suppliers. Its core product is CardioPRIME, an adult human primary cardiomyocyte platform that simultaneously predicts drug-induced inotropic and pro-arrhythmia risk and has demonstrated 96% sensitivity and 100% specificity against a benchmarked reference set; the platform was further extended in February 2023 via a University of Louisville cardiac slice technology license.

AnaBios generates revenue through three principal streams: (1) preclinical contract research services (functional assays, translational studies, custom study design) billed on a quote-based, multi-year contract model with 24-48 hour response cycles; (2) one-time product sales of human tissue samples and primary cells (hepatocytes, precision-cut lung slices, heart, brain, kidney, DRG, and spinal cord tissue, plus acquired Cell Systems primary cells and media); and (3) technology licensing income. Distribution is primarily direct enterprise sales, supplemented by exclusive regional channel partnerships with FUJIFILM in Japan and Chayon Laboratories in South Korea. The company is privately held and backed by Ampersand Capital Partners, which invested in 2022 and financed the April 2023 acquisition of Cell Systems, adding a Kirkland, Washington operating site and a primary cell and cell culture media portfolio.

AnaBios' customer base includes global pharmaceutical enterprises (Sanofi, Amgen, Novartis, Cytokinetics, Regeneron, Continuum Therapeutics) collaborating on cardiac safety, heart failure, pain, pulmonary fibrosis, and COVID-19-related programs, supplemented by an annual Translational Research Grant program that engages academic researchers such as Gatehouse Bio and Auburn University. The company also holds an FDA grant (U01FD006879) for cardiomyocyte-based pro-arrhythmia biomarker development, and its VP of R&D co-chairs the ion channel group of the FDA's CiPA initiative, embedding AnaBios within US regulatory science for cardiac safety.

Short descriptiontext

AnaBios is a San Diego-based preclinical CRO that supplies ethically procured human tissue and functional assays — including its CardioPRIME cardiac safety platform — to pharmaceutical, biotech, and academic clients for translational drug discovery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical contract research, human tissue assays, cardiac safety assessment, drug discovery services, translational research
Industry1 code
PRIMARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Preclinical Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Research Services
TypeProfessional Services
Description

AnaBios provides preclinical contract research organization (CRO) services to pharmaceutical companies, biotech firms, and academic laboratories globally, conducting functional assays and translational studies on human tissue and cells to de-risk drug development programs.

anabios.com
2Human Tissue and Cell Products
TypeOne Time License
Description

Sale of high-quality human tissue samples (hepatocytes, heart tissue, DRG tissue, brain tissue, lung slices, kidney tissue, spinal cord) and primary cells from ethically consented donors, with proprietary preservation methods ensuring physiological function.

anabios.com
3Technology Licensing
TypeLicensing Royalties
Description

Non-exclusive and exclusive technology transfer and license agreements for proprietary platforms, including the University of Louisville cardiac slice technology and CardioPRIME platform, for drug discovery applications.

anabios.com
4Regional Partnership Revenue
TypeOthers
Description

Revenue generated through exclusive regional partnerships such as FUJIFILM in Japan and Chayon Laboratories in South Korea, distributing AnaBios human tissue products and services through local partners.

anabios.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Pricing details1 tier
1Customized study pricing based on assay complexity, tissue type, and program stage
ModelOtherBilling cadenceMulti-year contract
Notes

Studies are tailored to client target, mechanism, and development stage. Quote-based pricing with 24-48 hour response time. Translational Research Grant offers up to $15,000 in human tissue products to academic winners.

anabios.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AnaBios is a preclinical contract research organization that supplies ethically-sourced human tissue samples (hepatocytes, heart, lung, brain, kidney, DRG, spinal cord) and proprietary functional assay services for drug discovery and translational research. Its flagship CardioPRIME platform uses adult human primary cardiomyocytes to predict drug-induced inotropic and pro-arrhythmia risk, supported by pain, lung, kidney, and neurotoxicity assay services. It also distributes primary cells and media kits from its acquired Cell Systems subsidiary.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 96% sensitivity and 100% specificity in detecting torsadogenic drugs at 10-fold free therapeutic plasma concentration
+4 more records
Product overview1 text field

AnaBios is a preclinical contract research organization (CRO) offering a unified platform of human tissue-based products and functional assay services for drug discovery and translational research. The core offerings include: (1) a portfolio of ethically-sourced human tissue products including hepatocytes, precision-cut lung slices, heart tissue, brain tissue, kidney tissue, DRG tissue, and spinal cord tissue, all procured through US-based hospitals and organ procurement organizations; (2) the proprietary CardioPRIME functional assay platform for cardiac safety assessment using adult human primary cardiomyocytes; (3) functional assay services spanning heart tissue assays, pain-related assays using DRG and spinal cord tissue, lung-related services, kidney-related services, and neurotoxicity assays; (4) acquired primary cell and media products from Cell Systems for 2D/3D and microfluidic research; and (5) licensed human cardiac slice technology from the University of Louisville. The company also operates a Translational Research Grant Award program providing tissue samples to academic researchers.

Product and service1 record
1CardioPRIME
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-02-14
Description

Non-exclusive technology transfer and license agreement with the University of Louisville for human cardiac slice technology developed by Dr. Tamer M. A. Mohamed. The technology enables researchers to maintain functioning human heart tissue in the laboratory for nearly two weeks. AnaBios incorporated this into its CardioPRIME platform for expanded capabilities in translational cardiac research.

2U.S. Food and Drug Administration (FDA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-09-17
Description

FDA awarded AnaBios grant U01FD006879 to develop a preclinical biomarker to identify pro-arrhythmia risk of potential drugs based on contractility measurements in human adult primary cardiomyocytes. FDA scientists have concluded that human tissue studies more accurately predict clinical outcomes than traditional preclinical models.

anabios.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-02-08
Description

Partnership to develop a new treatment for atrial fibrillation, focusing on compounds designed to modulate a novel cardiac ion channel target. AnaBios acquired development and commercialization rights to an entire family of promising compounds addressing the global atrial fibrillation market (estimated $16.17 billion by 2020). CardioPRIME technology was employed to optimize efficacy and safety of the molecules.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-22
Description

First-of-its-kind preclinical ex-vivo human cardiac research collaboration with Amgen, published in Frontiers in Physiology. Demonstrated that isolated human heart-based model combined with a newly-developed pro-arrhythmic score can differentiate between pro-arrhythmic and non-pro-arrhythmic compounds with greater predictivity than stem cell-derived models.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive Japan-only partnership where FUJIFILM distributes AnaBios human translational research services, leveraging its local presence and scientific infrastructure to serve pharmaceutical and biotechnology companies in Japan with high-quality human-relevant research services.

6Chayon Laboratories
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with Chayon Laboratories to expand access to high-quality human tissue samples and specialized research services in South Korea. Combines AnaBios expertise in functional human tissue assays with Chayon Laboratories' tissue procurement and processing capabilities.

anabios.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative study co-authored with Cytokinetics published on bioRxiv, highlighting the power of human-relevant translational models to advance research in cardiac hypercontractility and heart failure with preserved ejection fraction (HFpEF). Work integrates mechanistic biochemistry with functional data from human cardiomyocytes and engineered heart tissues.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Gatehouse Bio CEO Dr. David W. Salzman won AnaBios 2024 Translational Research Grant Award, receiving up to $15,000 in human precision-cut lung slices to advance drug development in idiopathic pulmonary fibrosis using AnaBios human tissue models.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioIVT is a leading supplier of human biological specimens and tissues for research, including hepatocytes and other primary cells used in drug discovery. It is the most directly comparable competitor to AnaBios's human tissue product line, with overlapping customer base among pharma preclinical researchers.

TypeDirect peer
Description

SEKISUI XenoTech specializes in human hepatocytes, subcellular fractions, and ADME/DMPK services for drug metabolism and toxicity studies. It directly competes with AnaBios in human hepatocyte supply and hepatic drug metabolism assay services.

TypeDirect peer
Description

Inotiv is a preclinical contract research organization offering safety assessment, toxicology, and drug discovery services. It competes with AnaBios in cardiac safety and broader preclinical CRO services for pharmaceutical clients.

TypeDirect peer
Description

Metrion Biosciences is a specialty CRO focused on cardiac safety pharmacology, ion channel screening, and electrophysiology services. It directly competes with AnaBios's CardioPRIME and ion channel cardiac safety offering.

TypeEmerging player
Description

Ncardia develops iPSC-derived cardiomyocytes and other cell types for cardiac safety and drug discovery applications. It competes with AnaBios's primary tissue approach using scalable iPSC alternatives, particularly for customers prioritizing consistency and supply scalability.

TypeEmerging player
Description

FUJIFILM Cellular Dynamics is a leading iPSC-derived cell manufacturer including iCell cardiomyocytes for cardiac safety assessment. It is both an indirect competitor to AnaBios and the parent of FUJIFILM—AnaBios's exclusive Japan distribution partner.

TypeBroad incumbent
Description

Charles River is a large preclinical and clinical CRO offering safety assessment, cardiac safety, and discovery services, including legacy ChanTest and Icagen capabilities (AnaBios CCO Dr. Chris Mathes's prior employer). It competes broadly with AnaBios across pharma CRO services.

TypeBroad incumbent
Description

Lonza is a global CDMO and cell manufacturing leader offering primary cells, media, and broader preclinical services. It competes with AnaBios in primary cells and adjacent cell-based drug discovery services at a much larger scale.

TypeBroad incumbent
Description

Eurofins Discovery is a broad preclinical CRO providing in vitro ADME, safety pharmacology, and drug discovery services. It competes with AnaBios in cardiac safety, ADME, and broader preclinical assay services through extensive global infrastructure.

TypeEmerging player
Description

Axol Bioscience manufactures iPSC-derived cardiomyocytes, neurons, and other cell types for drug discovery and safety assessment. It represents an emerging iPSC-based alternative to AnaBios's adult primary human tissue platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AnaBios

Preclinical Contract Research Servicesanabios.com

AnaBios is a San Diego-based preclinical CRO that supplies ethically procured human tissue and functional assays — including its CardioPRIME cardiac safety platform — to pharmaceutical, biotech, and academic clients for translational drug discovery.

What AnaBios does

AnaBios is a San Diego-based preclinical contract research organization founded in 2008 that provides human tissue-based translational research services to pharmaceutical, biotechnology, and academic clients. The company procures ethically consented adult human tissue and primary cells through an extensive network of US hospitals and organ procurement organizations, and applies proprietary preservation methods to deliver specimens with RNA Integrity Number scores 25-40% higher than competing suppliers. Its core product is CardioPRIME, an adult human primary cardiomyocyte platform that simultaneously predicts drug-induced inotropic and pro-arrhythmia risk and has demonstrated 96% sensitivity and 100% specificity against a benchmarked reference set; the platform was further extended in February 2023 via a University of Louisville cardiac slice technology license.

AnaBios generates revenue through three principal streams: (1) preclinical contract research services (functional assays, translational studies, custom study design) billed on a quote-based, multi-year contract model with 24-48 hour response cycles; (2) one-time product sales of human tissue samples and primary cells (hepatocytes, precision-cut lung slices, heart, brain, kidney, DRG, and spinal cord tissue, plus acquired Cell Systems primary cells and media); and (3) technology licensing income. Distribution is primarily direct enterprise sales, supplemented by exclusive regional channel partnerships with FUJIFILM in Japan and Chayon Laboratories in South Korea. The company is privately held and backed by Ampersand Capital Partners, which invested in 2022 and financed the April 2023 acquisition of Cell Systems, adding a Kirkland, Washington operating site and a primary cell and cell culture media portfolio.

AnaBios' customer base includes global pharmaceutical enterprises (Sanofi, Amgen, Novartis, Cytokinetics, Regeneron, Continuum Therapeutics) collaborating on cardiac safety, heart failure, pain, pulmonary fibrosis, and COVID-19-related programs, supplemented by an annual Translational Research Grant program that engages academic researchers such as Gatehouse Bio and Auburn University. The company also holds an FDA grant (U01FD006879) for cardiomyocyte-based pro-arrhythmia biomarker development, and its VP of R&D co-chairs the ion channel group of the FDA's CiPA initiative, embedding AnaBios within US regulatory science for cardiac safety.

AnaBios firmographics

Firmographics
Name
AnaBios
Legal name
AnaBios Corporation
Website
https://anabios.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
AnaBios is a San Diego-based preclinical CRO that supplies ethically procured human tissue and functional assays — including its CardioPRIME cardiac safety platform — to pharmaceutical, biotech, and academic clients for translational drug discovery.
Ownership category
akta.pro rank

AnaBios industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Preclinical contract research
  • Human tissue assays
  • Cardiac safety assessment
  • Drug discovery services
  • Translational research

Where AnaBios is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

AnaBios business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: AnaBios provides preclinical contract research organization (CRO) services to pharmaceutical companies, biotech firms, and academic laboratories globally, conducting functional assays and translational studies on human tissue and cells to de-risk drug development programs.
  2. Human Tissue and Cell Products: Sale of high-quality human tissue samples (hepatocytes, heart tissue, DRG tissue, brain tissue, lung slices, kidney tissue, spinal cord) and primary cells from ethically consented donors, with proprietary preservation methods ensuring physiological function.
  3. Technology Licensing: Non-exclusive and exclusive technology transfer and license agreements for proprietary platforms, including the University of Louisville cardiac slice technology and CardioPRIME platform, for drug discovery applications.
  4. Regional Partnership Revenue: Revenue generated through exclusive regional partnerships such as FUJIFILM in Japan and Chayon Laboratories in South Korea, distributing AnaBios human tissue products and services through local partners.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustomized study pricing based on assay complexity, tissue type, and program stage

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

AnaBios product offering

Product offering

Core offering

AnaBios is a preclinical contract research organization that supplies ethically-sourced human tissue samples (hepatocytes, heart, lung, brain, kidney, DRG, spinal cord) and proprietary functional assay services for drug discovery and translational research. Its flagship CardioPRIME platform uses adult human primary cardiomyocytes to predict drug-induced inotropic and pro-arrhythmia risk, supported by pain, lung, kidney, and neurotoxicity assay services. It also distributes primary cells and media kits from its acquired Cell Systems subsidiary.

Product overview

AnaBios is a preclinical contract research organization (CRO) offering a unified platform of human tissue-based products and functional assay services for drug discovery and translational research. The core offerings include: (1) a portfolio of ethically-sourced human tissue products including hepatocytes, precision-cut lung slices, heart tissue, brain tissue, kidney tissue, DRG tissue, and spinal cord tissue, all procured through US-based hospitals and organ procurement organizations; (2) the proprietary CardioPRIME functional assay platform for cardiac safety assessment using adult human primary cardiomyocytes; (3) functional assay services spanning heart tissue assays, pain-related assays using DRG and spinal cord tissue, lung-related services, kidney-related services, and neurotoxicity assays; (4) acquired primary cell and media products from Cell Systems for 2D/3D and microfluidic research; and (5) licensed human cardiac slice technology from the University of Louisville. The company also operates a Translational Research Grant Award program providing tissue samples to academic researchers.

Differentiator

Problem solved

Functional benefit

Products and services

  • CardioPRIME

Quantifiable outcome

  • 96% sensitivity and 100% specificity in detecting torsadogenic drugs at 10-fold free therapeutic plasma concentration
  • +4 more outcomes

Companies that use AnaBios

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

AnaBios technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

AnaBios partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • University of LouisvillecoreTechnology or Integration · 14 February 2023Non-exclusive technology transfer and license agreement with the University of Louisville for human cardiac slice technology developed by Dr. Tamer M. A. Mohamed. The technology enables researchers to maintain functioning human heart tissue in the laboratory for nearly two weeks. AnaBios incorporated this into its CardioPRIME platform for expanded capabilities in translational cardiac research.
  • U.S. Food and Drug Administration (FDA)coreStrategic or Co-development Partner · 17 September 2019FDA awarded AnaBios grant U01FD006879 to develop a preclinical biomarker to identify pro-arrhythmia risk of potential drugs based on contractility measurements in human adult primary cardiomyocytes. FDA scientists have concluded that human tissue studies more accurately predict clinical outcomes than traditional preclinical models.
  • SanoficoreStrategic or Co-development Partner · 8 February 2018Partnership to develop a new treatment for atrial fibrillation, focusing on compounds designed to modulate a novel cardiac ion channel target. AnaBios acquired development and commercialization rights to an entire family of promising compounds addressing the global atrial fibrillation market (estimated $16.17 billion by 2020). CardioPRIME technology was employed to optimize efficacy and safety of the molecules.
  • AmgencoreStrategic or Co-development Partner · 22 January 2018First-of-its-kind preclinical ex-vivo human cardiac research collaboration with Amgen, published in Frontiers in Physiology. Demonstrated that isolated human heart-based model combined with a newly-developed pro-arrhythmic score can differentiate between pro-arrhythmic and non-pro-arrhythmic compounds with greater predictivity than stem cell-derived models.
  • FUJIFILMcoreChannel Partner/ Reseller/ DistributorExclusive Japan-only partnership where FUJIFILM distributes AnaBios human translational research services, leveraging its local presence and scientific infrastructure to serve pharmaceutical and biotechnology companies in Japan with high-quality human-relevant research services.
  • Chayon LaboratoriescoreChannel Partner/ Reseller/ DistributorPartnership with Chayon Laboratories to expand access to high-quality human tissue samples and specialized research services in South Korea. Combines AnaBios expertise in functional human tissue assays with Chayon Laboratories' tissue procurement and processing capabilities.
  • CytokineticscoreStrategic or Co-development PartnerCollaborative study co-authored with Cytokinetics published on bioRxiv, highlighting the power of human-relevant translational models to advance research in cardiac hypercontractility and heart failure with preserved ejection fraction (HFpEF). Work integrates mechanistic biochemistry with functional data from human cardiomyocytes and engineered heart tissues.
  • Gatehouse BiominorStrategic or Co-development PartnerGatehouse Bio CEO Dr. David W. Salzman won AnaBios 2024 Translational Research Grant Award, receiving up to $15,000 in human precision-cut lung slices to advance drug development in idiopathic pulmonary fibrosis using AnaBios human tissue models.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

AnaBios competitors and assessment

Company assessment

Direct peers

  • BioIVT: BioIVT is a leading supplier of human biological specimens and tissues for research, including hepatocytes and other primary cells used in drug discovery. It is the most directly comparable competitor to AnaBios's human tissue product line, with overlapping customer base among pharma preclinical researchers.
  • SEKISUI XenoTech: SEKISUI XenoTech specializes in human hepatocytes, subcellular fractions, and ADME/DMPK services for drug metabolism and toxicity studies. It directly competes with AnaBios in human hepatocyte supply and hepatic drug metabolism assay services.
  • Inotiv: Inotiv is a preclinical contract research organization offering safety assessment, toxicology, and drug discovery services. It competes with AnaBios in cardiac safety and broader preclinical CRO services for pharmaceutical clients.
  • Metrion Biosciences: Metrion Biosciences is a specialty CRO focused on cardiac safety pharmacology, ion channel screening, and electrophysiology services. It directly competes with AnaBios's CardioPRIME and ion channel cardiac safety offering.

Emerging players

  • Ncardia: Ncardia develops iPSC-derived cardiomyocytes and other cell types for cardiac safety and drug discovery applications. It competes with AnaBios's primary tissue approach using scalable iPSC alternatives, particularly for customers prioritizing consistency and supply scalability.
  • Cellular Dynamics International (FUJIFILM): FUJIFILM Cellular Dynamics is a leading iPSC-derived cell manufacturer including iCell cardiomyocytes for cardiac safety assessment. It is both an indirect competitor to AnaBios and the parent of FUJIFILM—AnaBios's exclusive Japan distribution partner.
  • Axol Bioscience: Axol Bioscience manufactures iPSC-derived cardiomyocytes, neurons, and other cell types for drug discovery and safety assessment. It represents an emerging iPSC-based alternative to AnaBios's adult primary human tissue platform.

Broad incumbents

  • Charles River Laboratories: Charles River is a large preclinical and clinical CRO offering safety assessment, cardiac safety, and discovery services, including legacy ChanTest and Icagen capabilities (AnaBios CCO Dr. Chris Mathes's prior employer). It competes broadly with AnaBios across pharma CRO services.
  • Lonza: Lonza is a global CDMO and cell manufacturing leader offering primary cells, media, and broader preclinical services. It competes with AnaBios in primary cells and adjacent cell-based drug discovery services at a much larger scale.
  • Eurofins Discovery: Eurofins Discovery is a broad preclinical CRO providing in vitro ADME, safety pharmacology, and drug discovery services. It competes with AnaBios in cardiac safety, ADME, and broader preclinical assay services through extensive global infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

AnaBios social profiles

Digital presence

AnaBios compliance and trust

Trust signal

Compliance3 records

AnaBios financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AnaBios leadership team

Management profile

Number of profiles

Profiles7 records

AnaBios subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

AnaBios funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AnaBios M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AnaBios

What does AnaBios do?

AnaBios is a preclinical contract research organization that supplies ethically-sourced human tissue samples (hepatocytes, heart, lung, brain, kidney, DRG, spinal cord) and proprietary functional assay services for drug discovery and translational research. Its flagship CardioPRIME platform uses adult human primary cardiomyocytes to predict drug-induced inotropic and pro-arrhythmia risk, supported by pain, lung, kidney, and neurotoxicity assay services. It also distributes primary cells and media kits from its acquired Cell Systems subsidiary.

Is AnaBios a public or private company?

AnaBios is a private company. It is classified as private equity controlled and is currently operating.

When was AnaBios founded?

AnaBios was founded in 2008. It employs 11 to 50 people.

Where is AnaBios based?

AnaBios is headquartered in San Diego, United States, in the North America region.

How does AnaBios make money?

Four revenue lines are on record. Contract Research Services are the primary driver. The others are human Tissue and Cell Products, technology Licensing and regional Partnership Revenue.

Who are AnaBios's main competitors?

Direct peers on record are BioIVT, SEKISUI XenoTech, Inotiv and Metrion Biosciences. Emerging players are Ncardia, Cellular Dynamics International (FUJIFILM) and Axol Bioscience. Broad incumbents are Charles River Laboratories, Lonza and Eurofins Discovery.

Does AnaBios have an API?

No public API is recorded for AnaBios.

What industry is AnaBios in?

AnaBios's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comSegment Evaluation and Major Growth Areas in the Primary Cells MarketThe primary cells market is projected to reach $2.68 billion by 2030, growing at a compound annual growth rate of 9.9%, driven by demand in precision medicine, drug discovery, and regenerative medicine research. In April 2023, US-based AnaBios Corporation acquired Cell Systems to expand its human tissue and cell portfolio for research purposes. In July 2024, India-based Bioserve Biotechnologies launched advanced stem cell products under the REPROCELL brand to support scientific research and drug development.FierceBiotechAnaBios acquires cell culture media group for undisclosed priceAnaBios acquired Cell Systems, a provider of human primary cells, for an undisclosed price. The deal, financed by existing investors including Ampersand Capital Partners, expands AnaBios's portfolio of human tissue and cells. The company aims to enhance translational tools for researchers.Pharmaceutical TechnologyAnabios boosts human tissue portfolio with Cell Systems dealAnaBios has acquired Cell Systems, a Kirkland-based provider of human primary cells and cell culture media, to strengthen its human tissue portfolio. This strategic move aims to accelerate drug discovery and enhance translational research capabilities for pharmaceutical and academic clients through combined synergies. The transaction was supported financially by AnaBios' existing investors, including Ampersand Capital Partners.socaltech.comAnaBios Acquires Cell SystemsSan Diego-based AnaBios has acquired Kirkland, Washington-based Cell Systems to expand its portfolio of human tissue and cells. The financial terms of the acquisition were not disclosed. Cell Systems provides human primary cells for medical research in areas such as the brain, liver, and kidney.GlobeNewswireAnaBios Boosts Discovery of Safer, More Effective Medicines With License From the University of LouisvilleAnaBios announced a license agreement with the University of Louisville to incorporate human cardiac slice technology into its CardioPRIME platform. The technology maintains native heart tissue for nearly two weeks, extending experimental lifespan from under 24 hours. The deal aims to accelerate discovery of safer, more effective medicines.GlobeNewswireAnaBios Announces Inaugural Translational Research Conference to Be Held in San DiegoAnaBios announced its inaugural Translational Research Conference will be held Feb. 27-28, 2023, in San Diego, California. The two-day event will feature 15 speakers, including keynotes from Dr. Ted Price and Dr. Kalyanam Shivkumar, focusing on human-centered preclinical models.BioSpaceAnaBios Further Expands Business Development Team With Hiring of Dr. Blake AnsonAnaBios hired Blake Anson, Ph.D., as Vice President of Business Development, joining from Stemonix. The company also promoted Dr. Richard Kondo to VP of Business Development. The hires aim to expand AnaBios' global contract research outreach.GlobeNewswireAnaBios Further Expands Business Development Team With Hiring of Dr. Blake AnsonAnaBios hired Blake Anson as Vice President of Business Development, joining from Stemonix. The company also promoted Dr. Richard Kondo to VP of Business Development. The hires aim to expand global growth of contract research outreach.AnabiosAnaBios | Human Tissue and CellsAnaBios provides high-quality human tissue and cells for drug discovery, leveraging proprietary platforms to generate physiologically relevant data that improves clinical outcome prediction. The company recently co-authored a study with Cytokinetics published on bioRxiv, demonstrating how human-relevant models can advance research into cardiac dysfunction and heart failure therapies.GlobeNewswireAnaBios Introduces High-Quality Human Primary Liver Cells for Preclinical Drug DiscoveryAnaBios announced it will start selling high-quality human primary liver cells to pharmaceutical, biotech, and academic labs for preclinical drug discovery. The cells are isolated from ethically consented donors and are used for ADME profiling and hepatotoxicity testing. Orlando Mendoza was appointed business development manager for the new liver cell business.